Clinical Trials
52 trialsA Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
POE14-01
Stanford University
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Anhui Provincial Hospital
Lentivirally Redirected CD123 Autologous T Cells in AML
University of Pennsylvania
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Dana-Farber Cancer Institute
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
M.D. Anderson Cancer Center
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Loyola University
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Celularity Incorporated
Cord Blood Expansion on Mesenchymal Stem Cells
M.D. Anderson Cancer Center
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
ADVL
Baylor College of Medicine
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
University of Maryland, Baltimore
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
University of Pittsburgh
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
Memorial Sloan Kettering Cancer Center
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Stanford University
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
St. Jude Children's Research Hospital
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Emory University
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Children's Oncology Group
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
M.D. Anderson Cancer Center
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins